EGFR and non-small cell lung carcinoma: EGFR‐TKI therapy has improved the survival and quality of life outcomes for NSCLC patients harboring EGFR mutations.4, 5, 6, 7, 8, 9, 10, 14, 15 Although several studies have shown that chemotherapy has an important role in improving the prognosis in EGFR‐mutated NSCLC patients,8, 9, 10 a proportion of patients miss the opportunity to receive subsequent chemotherapy.10, 11, 12 In the present study, the initiation of subsequent chemotherapy after EGFR‐TKI therapy contributed to a better prognosis, regardless of the number of metastatic organs.